Skip to main content
Top
Published in: Diabetologia 1/2008

01-01-2008 | Article

Glucose fluctuations and activation of oxidative stress in patients with type 1 diabetes

Authors: I. M. E. Wentholt, W. Kulik, R. P. J. Michels, J. B. L Hoekstra, J. H. DeVries

Published in: Diabetologia | Issue 1/2008

Login to get access

Abstract

Aims/hypothesis

Glucose fluctuations may help predict diabetic complications. We evaluated the relation between glucose variability and oxidative stress in patients with type 1 diabetes.

Methods

Continuous glucose monitors were inserted subcutaneously in 25 patients. During the measurement, patients collected two 24 h urine samples, while 24 healthy controls collected one 24 h urine sample for determination of 15(S)-8-iso-prostaglandin \( {\text{F}}_{{2\alpha }} {\left( {{\text{PGF}}_{{2\alpha }} } \right)} \) using HPLC tandem mass spectrometry. Mean of the daily differences (MODD), mean amplitude of glycaemic excursions (MAGE) and continuous overlapping net glycaemic action calculated with n hour time-intervals (CONGA-n) were calculated as markers for glucose variability and correlation with \( 15{\left( S \right)} - 8 - iso - {\text{PGF}}_{{2\alpha }} \) excretion was calculated.

Results

Median [interquartile range (IQR)] urinary \( 15{\left( S \right)} - 8 - iso - {\text{PGF}}_{{2\alpha }} \) was higher in patients than healthy controls: 161 (140–217) pg/mg creatinine vs 118 (101–146) pg/mg creatinine (p = 0.001). Median (IQR) MODD was 3.7 (3.2–5.0) mmol/l, MAGE 7.6 (6.4–9.0) mmol/l and CONGA-1 2.3 (2.1–2.8) mmol/l. Univariate regression did not reveal an association for MODD (r 2 = 0.01), MAGE (0.08) or CONGA-1 (0.07) with \( 15{\left( S \right)} - 8 - iso - {\text{PGF}}_{{2\alpha }} \) excretion, nor was an association revealed when corrected for HbA1c, age, sex and smoking. Spearman correlation coefficients (r) between \( 15{\left( S \right)} - 8 - iso - {\text{PGF}}_{{2\alpha }} \) excretion and MODD, MAGE and CONGA-1 were non-significant: −0.112, −0.381 and −0.177.

Conclusions/interpretation

We report that there is no relationship between glucose variability and urinary \( 15{\left( S \right)} - 8 - iso - {\text{PGF}}_{{2\alpha }} \). We also confirm that patients with type 1 diabetes have higher levels of urinary \( 15{\left( S \right)} - 8 - iso - {\text{PGF}}_{{2\alpha }} \) than healthy controls, suggesting that in addition to glucose variability, other factors favouring oxidative stress may exist. We did not see a relation between high glucose variability and elevated levels of oxidative stress in patients with type 1 diabetes.
Literature
1.
go back to reference The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986CrossRef The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986CrossRef
3.
go back to reference Brownlee M (2005) The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54:1615–1625PubMedCrossRef Brownlee M (2005) The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54:1615–1625PubMedCrossRef
4.
go back to reference Monnier LH, Lachkar H, Richard JL et al (1984) Plasma beta-thromboglobulin response to insulin-induced hypoglycemia in type I diabetic patients. Diabetes 33:907–909PubMedCrossRef Monnier LH, Lachkar H, Richard JL et al (1984) Plasma beta-thromboglobulin response to insulin-induced hypoglycemia in type I diabetic patients. Diabetes 33:907–909PubMedCrossRef
5.
go back to reference Trovati M, Anfossi G, Cavalot F et al (1986) Studies on mechanisms involved in hypoglycemia-induced platelet activation. Diabetes 35:818–825PubMedCrossRef Trovati M, Anfossi G, Cavalot F et al (1986) Studies on mechanisms involved in hypoglycemia-induced platelet activation. Diabetes 35:818–825PubMedCrossRef
6.
go back to reference Boland E, Monsod T, Delucia M, Brandt CA, Fernando S, Tamborlane WV (2001) Limitations of conventional methods of self-monitoring of blood glucose: lessons learned from 3 days of continuous glucose sensing in pediatric patients with type 1 diabetes. Diabetes Care 24:1858–1862PubMedCrossRef Boland E, Monsod T, Delucia M, Brandt CA, Fernando S, Tamborlane WV (2001) Limitations of conventional methods of self-monitoring of blood glucose: lessons learned from 3 days of continuous glucose sensing in pediatric patients with type 1 diabetes. Diabetes Care 24:1858–1862PubMedCrossRef
7.
go back to reference Ceriello A, Motz E (2004) Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol 24:816–823PubMedCrossRef Ceriello A, Motz E (2004) Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol 24:816–823PubMedCrossRef
8.
go back to reference Salardi S, Zucchini S, Santoni R et al (2002) The glucose area under the profiles obtained with continuous glucose monitoring system relationships with HbA(lc) in pediatric type 1 diabetic patients. Diabetes Care 25:1840–1844PubMedCrossRef Salardi S, Zucchini S, Santoni R et al (2002) The glucose area under the profiles obtained with continuous glucose monitoring system relationships with HbA(lc) in pediatric type 1 diabetic patients. Diabetes Care 25:1840–1844PubMedCrossRef
9.
go back to reference Kilpatrick ES, Rigby AS, Atkin SL (2006) The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 29:1486–1490PubMedCrossRef Kilpatrick ES, Rigby AS, Atkin SL (2006) The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 29:1486–1490PubMedCrossRef
10.
go back to reference Nathan DM, Cleary PA, Backlund JY et al (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643–2653PubMedCrossRef Nathan DM, Cleary PA, Backlund JY et al (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643–2653PubMedCrossRef
11.
go back to reference Monnier L, Mas E, Ginet C et al (2006) Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 295:1681–1687PubMedCrossRef Monnier L, Mas E, Ginet C et al (2006) Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 295:1681–1687PubMedCrossRef
12.
go back to reference Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ (1990) A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci U S A 87:9383–9387PubMedCrossRef Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ (1990) A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci U S A 87:9383–9387PubMedCrossRef
13.
go back to reference Roberts LJ, Morrow JD (2000) Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo. Free Radic Biol Med 28:505–513PubMedCrossRef Roberts LJ, Morrow JD (2000) Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo. Free Radic Biol Med 28:505–513PubMedCrossRef
14.
go back to reference Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41PubMedCrossRef Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41PubMedCrossRef
15.
go back to reference Davi G, Ciabattoni G, Consoli A et al (1999) In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 99:224–229PubMed Davi G, Ciabattoni G, Consoli A et al (1999) In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 99:224–229PubMed
16.
go back to reference Meagher EA, Barry OP, Lawson JA, Rokach J, Fitzgerald GA (2001) Effects of vitamin E on lipid peroxidation in healthy persons. JAMA 285:1178–1182PubMedCrossRef Meagher EA, Barry OP, Lawson JA, Rokach J, Fitzgerald GA (2001) Effects of vitamin E on lipid peroxidation in healthy persons. JAMA 285:1178–1182PubMedCrossRef
17.
go back to reference Patrignani P, Panara MR, Tacconelli S et al (2000) Effects of vitamin E supplementation on F(2)-isoprostane and thromboxane biosynthesis in healthy cigarette smokers. Circulation 102:539–545PubMed Patrignani P, Panara MR, Tacconelli S et al (2000) Effects of vitamin E supplementation on F(2)-isoprostane and thromboxane biosynthesis in healthy cigarette smokers. Circulation 102:539–545PubMed
18.
go back to reference Reilly M, Delanty N, Lawson JA, Fitzgerald GA (1996) Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation 94:19–25PubMed Reilly M, Delanty N, Lawson JA, Fitzgerald GA (1996) Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation 94:19–25PubMed
19.
go back to reference McDonnell CM, Donath SM, Vidmar SI, Werther GA, Cameron FJ (2005) A novel approach to continuous glucose analysis utilizing glycemic variation. Diabetes Technol Ther 7:253–263PubMedCrossRef McDonnell CM, Donath SM, Vidmar SI, Werther GA, Cameron FJ (2005) A novel approach to continuous glucose analysis utilizing glycemic variation. Diabetes Technol Ther 7:253–263PubMedCrossRef
20.
go back to reference Molnar GD, Taylor WF, Ho MM (1972) Day-to-day variation of continuously monitored glycaemia: a further measure of diabetic instability. Diabetologia 8:342–348PubMedCrossRef Molnar GD, Taylor WF, Ho MM (1972) Day-to-day variation of continuously monitored glycaemia: a further measure of diabetic instability. Diabetologia 8:342–348PubMedCrossRef
21.
go back to reference Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF (1970) Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 19:644–655PubMed Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF (1970) Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 19:644–655PubMed
22.
go back to reference Praet SF, Manders RJ, Meex RC et al (2006) Glycaemic instability is an underestimated problem in Type II diabetes. Clin Sci (Lond) 111:119–126CrossRef Praet SF, Manders RJ, Meex RC et al (2006) Glycaemic instability is an underestimated problem in Type II diabetes. Clin Sci (Lond) 111:119–126CrossRef
23.
go back to reference Flores L, Rodela S, Abian J, Claria J, Esmatjes E (2004) F2 isoprostane is already increased at the onset of type 1 diabetes mellitus: effect of glycemic control. Metabolism 53:1118–1120PubMedCrossRef Flores L, Rodela S, Abian J, Claria J, Esmatjes E (2004) F2 isoprostane is already increased at the onset of type 1 diabetes mellitus: effect of glycemic control. Metabolism 53:1118–1120PubMedCrossRef
24.
go back to reference Block G, Dietrich M, Norkus EP et al (2002) Factors associated with oxidative stress in human populations. Am J Epidemiol 156:274–285PubMedCrossRef Block G, Dietrich M, Norkus EP et al (2002) Factors associated with oxidative stress in human populations. Am J Epidemiol 156:274–285PubMedCrossRef
25.
go back to reference Wang Z, Ciabattoni G, Creminon C et al (1995) Immunological characterization of urinary 8-epi-prostaglandin F2 alpha excretion in man. J Pharmacol Exp Ther 275:94–100PubMed Wang Z, Ciabattoni G, Creminon C et al (1995) Immunological characterization of urinary 8-epi-prostaglandin F2 alpha excretion in man. J Pharmacol Exp Ther 275:94–100PubMed
26.
go back to reference Morrow JD, Frei B, Longmire AW et al (1995) Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med 332:1198–1203PubMedCrossRef Morrow JD, Frei B, Longmire AW et al (1995) Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med 332:1198–1203PubMedCrossRef
27.
go back to reference Catella-Lawson F, Fitzgerald GA (1996) Oxidative stress and platelet activation in diabetes mellitus. Diabetes Res Clin Pract 30(Suppl):13–18PubMedCrossRef Catella-Lawson F, Fitzgerald GA (1996) Oxidative stress and platelet activation in diabetes mellitus. Diabetes Res Clin Pract 30(Suppl):13–18PubMedCrossRef
28.
go back to reference Chisolm GM, Irwin KC, Penn MS (1992) Lipoprotein oxidation and lipoprotein-induced cell injury in diabetes. Diabetes 41(Suppl 2):61–66PubMed Chisolm GM, Irwin KC, Penn MS (1992) Lipoprotein oxidation and lipoprotein-induced cell injury in diabetes. Diabetes 41(Suppl 2):61–66PubMed
29.
go back to reference Gopaul NK, Anggard EE, Mallet AI, Betteridge DJ, Wolff SP, Nourooz-Zadeh J (1995) Plasma 8-epi-PGF2 alpha levels are elevated in individuals with non-insulin dependent diabetes mellitus. FEBS Lett 368:225–229PubMedCrossRef Gopaul NK, Anggard EE, Mallet AI, Betteridge DJ, Wolff SP, Nourooz-Zadeh J (1995) Plasma 8-epi-PGF2 alpha levels are elevated in individuals with non-insulin dependent diabetes mellitus. FEBS Lett 368:225–229PubMedCrossRef
30.
go back to reference Ide T, Tsutsui H, Ohashi N et al (2002) Greater oxidative stress in healthy young men compared with premenopausal women. Arterioscler Thromb Vasc Biol 22:438–442PubMedCrossRef Ide T, Tsutsui H, Ohashi N et al (2002) Greater oxidative stress in healthy young men compared with premenopausal women. Arterioscler Thromb Vasc Biol 22:438–442PubMedCrossRef
31.
go back to reference Veglia F, Cighetti G, De FM et al (2006) Age- and gender-related oxidative status determined in healthy subjects by means of OXY-SCORE, a potential new comprehensive index. Biomarkers 11:562–573PubMedCrossRef Veglia F, Cighetti G, De FM et al (2006) Age- and gender-related oxidative status determined in healthy subjects by means of OXY-SCORE, a potential new comprehensive index. Biomarkers 11:562–573PubMedCrossRef
32.
go back to reference Maxwell S, Holm G, Bondjers G, Wiklund O (1997) Comparison of antioxidant activity in lipoprotein fractions from insulin-dependent diabetics and healthy controls. Atherosclerosis 129:89–96PubMedCrossRef Maxwell S, Holm G, Bondjers G, Wiklund O (1997) Comparison of antioxidant activity in lipoprotein fractions from insulin-dependent diabetics and healthy controls. Atherosclerosis 129:89–96PubMedCrossRef
33.
go back to reference Maxwell SR, Thomason H, Sandler D et al (1997) Antioxidant status in patients with uncomplicated insulin-dependent and non-insulin-dependent diabetes mellitus. Eur J Clin Invest 27:484–490PubMedCrossRef Maxwell SR, Thomason H, Sandler D et al (1997) Antioxidant status in patients with uncomplicated insulin-dependent and non-insulin-dependent diabetes mellitus. Eur J Clin Invest 27:484–490PubMedCrossRef
34.
go back to reference Santini SA, Marra G, Giardina B et al (1997) Defective plasma antioxidant defenses and enhanced susceptibility to lipid peroxidation in uncomplicated IDDM. Diabetes 46:1853–1858PubMedCrossRef Santini SA, Marra G, Giardina B et al (1997) Defective plasma antioxidant defenses and enhanced susceptibility to lipid peroxidation in uncomplicated IDDM. Diabetes 46:1853–1858PubMedCrossRef
35.
go back to reference Tsai EC, Hirsch IB, Brunzell JD, Chait A (1994) Reduced plasma peroxyl radical trapping capacity and increased susceptibility of LDL to oxidation in poorly controlled IDDM. Diabetes 43:1010–1014PubMedCrossRef Tsai EC, Hirsch IB, Brunzell JD, Chait A (1994) Reduced plasma peroxyl radical trapping capacity and increased susceptibility of LDL to oxidation in poorly controlled IDDM. Diabetes 43:1010–1014PubMedCrossRef
Metadata
Title
Glucose fluctuations and activation of oxidative stress in patients with type 1 diabetes
Authors
I. M. E. Wentholt
W. Kulik
R. P. J. Michels
J. B. L Hoekstra
J. H. DeVries
Publication date
01-01-2008
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 1/2008
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-007-0842-6

Other articles of this Issue 1/2008

Diabetologia 1/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine